KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Deferred Taxes: 2010-2025

Historic Deferred Taxes for Biomarin Pharmaceutical (BMRN) over the last 15 years, with Sep 2025 value amounting to -$13.6 million.

  • Biomarin Pharmaceutical's Deferred Taxes fell 212.11% to -$13.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.5 million, marking a year-over-year increase of 912.86%. This contributed to the annual value of $56.1 million for FY2024, which is 224.71% up from last year.
  • Biomarin Pharmaceutical's Deferred Taxes amounted to -$13.6 million in Q3 2025, which was down 140.93% from $33.3 million recorded in Q2 2025.
  • Biomarin Pharmaceutical's 5-year Deferred Taxes high stood at $42.4 million for Q4 2024, and its period low was -$51.3 million during Q4 2022.
  • Its 3-year average for Deferred Taxes is $5.4 million, with a median of $1.3 million in 2024.
  • In the last 5 years, Biomarin Pharmaceutical's Deferred Taxes plummeted by 1,330.99% in 2022 and then spiked by 9,875.09% in 2025.
  • Over the past 5 years, Biomarin Pharmaceutical's Deferred Taxes (Quarterly) stood at -$3.6 million in 2021, then tumbled by 1,330.99% to -$51.3 million in 2022, then skyrocketed by 51.61% to -$24.8 million in 2023, then spiked by 270.61% to $42.4 million in 2024, then slumped by 212.11% to -$13.6 million in 2025.
  • Its Deferred Taxes was -$13.6 million in Q3 2025, compared to $33.3 million in Q2 2025 and $28.4 million in Q1 2025.